Recent News

• 12.02.2025 - Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
• 11.26.2025 - Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
• 11.19.2025 - Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
• 11.17.2025 - Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
• 11.14.2025 - Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
• 11.14.2025 - Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
• 11.13.2025 - Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
• 11.13.2025 - Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 11.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.19.2025 - EX-99.1 EX-99.1
• 11.19.2025 - 8-K Current report
• 11.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.18.2025 - 8-K Current report
• 11.18.2025 - EX-99.1 EX-99.1
• 11.17.2025 - 8-K Current report
• 11.17.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities